Director (m/f/x), HAE / ANDEMBRY Brand Lead
CSL Seqirus
This listing was originally posted on CSL Seqirus's careers page. Formulate is an equal opportunity job aggregator and is not involved in the hiring process. Where salary information is estimated, it is derived from BLS industry benchmarks and may differ from actual compensation.
Drug products linked to this role
Upgrade to Pro to access the AI-generated 'Read before applying' briefing and other premium pharma intelligence.
Upgrade to Pro — $25/moInternational Marketing | Hereditary Angioedema
THE OPPORTUNITY
Shape the international HAE portfolio strategy and growth of ANDEMBRY, while defining the complementary positioning of ANDEMBRY and BERINERT across the patient journey. Partner across markets and functions to translate a strong portfolio and brand vision into locally relevant, compliant and measurable execution.
Role purpose
The Director, HAE / ANDEMBRY Brand Lead is responsible for developing and implementing the HAE disease-area and ANDEMBRY brand strategy for the International region. The role drives sustainable growth through market expansion, brand adoption and launch excellence, while shaping the complementary positioning of ANDEMBRY and BERINERT within the HAE portfolio. This requires a consistent international direction that affiliates can adapt to diverse local market needs.
As the marketing subject-matter expert and go-to partner for affiliates, the Director leads the ANDEMBRY International Brand Team (IBT) and enables cross-functional co-creation with affiliate teams, International Marketing and Global Commercial Development. The role translates strategy into integrated portfolio playbooks, programs and capabilities that affiliates can localize and execute effectively.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. Our parent company, CSL, headquartered in Melbourne, Australia, employs 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries.
To learn more about CSL, CSL Behring, CSL Seqirus and CSL Vifor visit https://www.csl.com/ and CSL Plasma at https://www.cslplasma.com/.
Our Benefits
For more information on CSL benefits visit How CSL Supports Your Well-being | CSL.
You Belong at CSL
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out. By celebrating our differences and creating a culture of curiosity and empathy, we are able to better understand and connect with our patients and donors, foster strong relationships with our stakeholders, and sustain a diverse workforce that will move our company and industry into the future.
To learn more about inclusion and belonging visit https://www.csl.com/careers/inclusion-and-belonging
Equal Opportunity Employer
CSL is an Equal Opportunity Employer. If you are an individual with a disability and need a reasonable accommodation for any part of the application process, please visit https://www.csl.com/accessibility-statement.
Explore related positions you might be interested in
We'll notify you when matching roles are posted.
Interviewed at CSL Seqirus?
Help others prepare — share your experience anonymously.
BIOTECHNOLOGY
Flu vaccine
Upgrade to Pro to access salary benchmarks and market rate data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo